3034 results for "Psilocybin"
Exploring Factors Affecting Psychological Flexibility After Psychedelic Experiences.
Journal of psychoactive drugs – April 25, 2025
Summary
Profound mystical experiences during psychedelic sessions with substances like LSD and psilocybin can lead to lasting improvements in psychological flexibility—our ability to adapt to life's challenges. People who reported more intense mystical experiences showed greater gains in mental adaptability, particularly in the month following their experience. These benefits align with principles of acceptance and commitment therapy.
Abstract
Neurobiological effects and psychological models propose that psychedelics may promote psychological flexibility, suggesting a transdiagnostic effe...
Exploring the Role of Psychedelics in Modulating Ego and Treating Neuropsychiatric Disorders.
ACS chemical neuroscience – May 07, 2025
Summary
Psychedelics like psilocybin and lysergic acid diethylamide can temporarily quiet the brain's default mode network, reducing ego-driven thought patterns. This disruption appears key in treating neuropsychiatric diseases. Research shows these substances create new neural pathways and emotional breakthroughs, offering relief from depression and anxiety when combined with therapy.
Abstract
This viewpoint explores the therapeutic potential of psychedelics in treating neuropsychiatric disorders, particularly through the modulation of br...
Motivation and retrospective appraisal of psychedelic study participation: a qualitative study in healthy volunteers.
Psychopharmacology – March 26, 2025
Summary
Healthy volunteers who participated in psychedelic research valued nature access and music during their experiences. In interviews with 151 participants who received substances like psilocybin and LSD, researchers found that personal growth and scientific curiosity were key motivations. Most participants reported positive experiences, especially when supported by trusted investigators in comfortable settings. Natural environments enhanced outcomes.
Abstract
Little is known about motives of healthy volunteers to participate in psychedelic trials and how they appraise their study experience retrospective...
Psychedelics and autobiographical memory - six open questions.
Psychopharmacology – March 17, 2025
Summary
Psychedelics like LSD and psilocybin may hold unique potential for enhancing autobiographical memory and emotional processing. Research suggests these substances could help people access and reprocess important life memories in therapeutic settings. Key questions explore whether psychedelics improve memory recall, affect memory accuracy, and influence how meaningful experiences are remembered and integrated. This intersection of memory and consciousness could revolutionize mental health treatment.
Abstract
Since the earliest LSD research, psychedelics have been claimed to enhance autobiographical memory. Revisiting and processing autobiographical memo...
The intensity of the psychedelic experience is reliably associated with clinical improvements: A systematic review and meta-analysis.
Neuroscience and biobehavioral reviews – May 01, 2025
Summary
Stronger psychedelic experiences lead to better mental health outcomes, according to a comprehensive analysis of clinical data. Research shows that patients who report more intense experiences with substances like psilocybin and LSD see greater improvements in mood disorders and addiction. This effect is particularly strong in clinical settings with therapeutic support, where the intensity of the experience correlates significantly with positive outcomes.
Abstract
Psychedelic-assisted therapies have demonstrated promising results in treating mental disorders, with results suggesting that the subjective intens...
Psychedelic Medicine Exceptionalism.
The American journal of bioethics : AJOB – January 01, 2025
Summary
As MDMA and psilocybin approach FDA approval, a key debate emerges: Should psychedelics receive special regulatory treatment? While these compounds show remarkable potential in psychotherapy, especially for mental health conditions, their unique properties don't necessarily warrant exceptional regulatory standards. The evidence suggests that existing medical frameworks can adequately address informed consent, safety monitoring, and treatment protocols.
Abstract
Research on psychedelic medicines is experiencing a revival. Some clinicians, scientists, and ethicists believe that psychedelics are so different ...
Practical considerations in the establishment of psychedelic research programs.
Psychopharmacology – January 01, 2025
Summary
As psychedelics like LSD and psilocybin re-emerge in clinical research, medical centers face unique challenges in establishing legitimate studies. Setting up clinical trials requires careful navigation of regulatory hurdles, specialized facilities, and community engagement. Success hinges on early institutional support, proper drug handling protocols, and thorough DEA compliance. Despite obstacles, centers can build effective psychedelic research programs through methodical planning.
Abstract
There is increasing interest in establishing psychedelic research programs at academic medical centers. However, psychedelics are intensely psychoa...
Anxiety and Affective Symptoms Related to the Use of Classic Psychedelics: A Systematic Review.
Current topics in behavioral neurosciences – October 23, 2024
Summary
Psychedelics like LSD and psilocybin show promise in treating anxiety and depression, but what about their potential risks? Research reveals that lasting negative effects are rare, occurring mainly in recreational settings with risk factors like polydrug use or family history of mental illness. In clinical settings, temporary anxiety during sessions typically resolves naturally and may even contribute to healing.
Abstract
There is a large and rapidly growing body of literature investigating the therapeutic effects of classic psychedelics in affective and anxiety diso...
Beyond the numbers: reimagining healing with psychedelics for eating disorders.
Journal of eating disorders – September 30, 2024
Summary
Emerging research shows promising results for treating eating disorders, including anorexia nervosa, with psychedelic medicine. Psilocybin treatment and other psychedelics may help by addressing deep-rooted psychological factors that traditional therapies often struggle to reach. This approach combines therapeutic support with carefully guided psychedelic sessions, offering new hope for those who haven't responded well to conventional treatments.
Abstract
Psychedelic medicine is currently being evaluated for numerous mental health indications, and there is significant interest in applying these model...
Mind over matter: the microbial mindscapes of psychedelics and the gut-brain axis.
Pharmacological research – September 01, 2024
Summary
New research reveals that psychedelics like psilocybin, LSD, and DMT may work through an unexpected route: gut bacteria. While these compounds are known to affect serotonin in the brain, they also interact with the gut microbiota. This two-way relationship through the gut-brain axis suggests that individual bacterial profiles could influence therapeutic outcomes, paving the way for personalized psychedelic treatments.
Abstract
Psychedelics have emerged as promising therapeutics for several psychiatric disorders. Hypotheses around their mechanisms have revolved around thei...
Brain Networks, Neurotransmitters and Psychedelics: Towards a Neurochemistry of Self-Awareness.
Current neurology and neuroscience reports – August 01, 2024
Summary
Psychedelics like LSD and psilocybin can dramatically alter how we experience ourselves and process emotions. Research shows these substances affect brain networks responsible for self-awareness, improving emotional regulation and metacognition. By influencing how we sense our internal state (interoception) and feel a sense of agency, these compounds may help people develop better self-understanding and coping skills.
Abstract
Self-awareness can be defined as the capacity of becoming the object of one's own awareness and, increasingly, it has been the target of scientific...
Psychedelic-assisted psychotherapy: where is the psychotherapy research?
Psychopharmacology – August 01, 2024
Summary
While psychedelic medicines like psilocybin show promise in mental health treatment, the therapy component of psychedelic-assisted psychotherapy remains understudied. Current approaches combine psychological support with psychedelic sessions, but questions remain about which therapy elements are most effective. Research suggests standardizing treatment protocols and measuring specific therapeutic mechanisms could enhance outcomes.
Abstract
Psychedelic-assisted psychotherapy (PAP) has emerged as a potential treatment for a variety of mental health conditions, including substance use di...
Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties.
Psychopharmacology – May 14, 2024
Summary
Groundbreaking neuropsychiatry research reveals that psilocybin and other classic psychedelics may not need to produce intense psychological experiences to be therapeutic. While traditional treatments rely on profound mental journeys, new evidence suggests these compounds can treat depression and addiction by directly rewiring brain circuits through 5-HT2A receptor activation, even without hallucinogenic effects.
Abstract
Recent research with classic psychedelics suggests significant therapeutic potential, particularly for neuropsychiatric disorders. A mediating infl...
Psychedelic substitution: altered substance use patterns following psychedelic use in a global survey.
Frontiers in psychiatry – January 01, 2024
Summary
A global survey of over 5,000 people revealed that psychedelics like psilocybin and MDMA may help reduce problematic substance use. 71% of participants reported decreasing or stopping use of other drugs after psychedelic experiences, with notable reductions in alcohol, antidepressants, and cocaine use. Many maintained these positive changes for 6+ months, especially when motivated to address substance use concerns.
Abstract
Recent research suggests that psychedelics may have potential for the treatment of various substance use disorders. However, most studies to date h...
Longitudinal associations between psychedelic use and unusual visual experiences in the United States and the United Kingdom.
Journal of psychopharmacology (Oxford, England) – January 01, 2024
Summary
First-time users of psychedelics like LSD and psilocybin are more likely to experience lasting visual effects after their initial experience. A large study tracking 7,667 adults in the US and UK found that people who used psychedelics reported increased unusual visual phenomena afterward, with newcomers showing the strongest effects. These changes suggest potential risks but were generally mild.
Abstract
Whereas findings from case reports and cross-sectional studies suggest that naturalistic psychedelic use may be associated with unusual visual expe...
Association of Hallucinogen Persisting Perception Disorder with Trait Neuroticism and Mental Health Symptoms.
Journal of psychoactive drugs – January 01, 2025
Summary
Visual disturbances after psychedelic use may be more common than previously thought. Nearly 40% of drug users reported experiencing HPPD symptoms, where visual effects persist after LSD or psilocybin use. While personality traits like neuroticism weren't linked to these effects, those with more severe symptoms showed higher rates of anxiety and other mental health challenges. Drug testing and verification emerged as a crucial safety factor.
Abstract
Hallucinogen Persisting Perception Disorder (HPPD) is considered rare in hallucinogen users although there are conflicting reports about its incide...
Preclinical models of treatment-resistant depression: challenges and perspectives.
Pharmacological reports : PR – December 01, 2023
Summary
Up to 60% of treatment-resistant depression cases may be influenced by biological factors like age and hormones. Animal models using Wistar Kyoto rats and chronic mild stress tests have helped evaluate promising treatments, including ketamine, deep brain stimulation, and psilocybin, offering new hope for patients who don't respond to traditional antidepressants.
Abstract
Treatment-resistant depression (TRD) is a subgroup of major depressive disorder in which the use of classical antidepressant treatments fails to ac...
Classic psychedelic use and current meditation practice.
Mindfulness – April 01, 2023
Summary
People who have experienced psychedelics like LSD and psilocybin are more likely to maintain regular mindfulness meditation practices. A large U.S. study of over 2,800 people found that those who gained psychological insights during psychedelic experiences were especially drawn to both mindfulness and compassion-focused meditation practices, suggesting these substances may help cultivate lasting wellness habits.
Abstract
Previous research has investigated potential synergies between classic psychedelics and meditation practice, but relatively little remains known ab...
A scoping review of the effects of serotonergic psychedelics on attitudes towards death.
Psychopharmacology – April 21, 2025
Summary
Serotonergic psychedelics show remarkable potential in transforming how people view mortality. Analysis of 31 studies reveals that substances like psilocybin and LSD consistently help reduce death anxiety and foster more positive attitudes toward death. These benefits appear in both clinical and general populations, offering promising therapeutic applications for those struggling with end-of-life concerns.
Abstract
Emerging evidence suggests that psychedelic experiences have the potential to change attitudes towards death and reduce death anxiety. Improved att...
"How Do I Learn More About this?": Utilization and Trust of Psychedelic Information Sources Among People Naturalistically Using Psychedelics.
Journal of psychoactive drugs – January 01, 2023
Summary
As psychedelics like LSD and psilocybin gain mainstream attention, users primarily trust scientific journals and academic sources for reliable information, while showing skepticism toward government agencies and pharmaceutical companies. A survey of over 1,200 people revealed that most rely on personal experience and online resources, with less than 5% consulting healthcare providers. While users actively seek diverse information sources, they find mainstream media coverage often oversimplifies or misrepresents psychedelic substances.
Abstract
There is a surge of interest in psychedelics, including new stakeholders and greater media attention. There is a need to examine the information-se...
Experiences of microdosing psychedelics in an attempt to support wellbeing and mental health.
BMC psychiatry – March 14, 2023
Summary
Small doses of psychedelics like LSD and psilocybin may offer mental health benefits, according to users who carefully track their experiences. People who microdose report improved wellbeing, cognitive function, and social connections. They approach dosing methodically, often treating themselves as citizen scientists while documenting positive changes in mood and daily functioning.
Abstract
Microdosing psychedelic drugs is a growing phenomenon, but little is known about the experiences surrounding this. Research broadly suggests that p...
Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics.
Journal of affective disorders – April 01, 2023
Summary
While most psychedelic experiences are manageable, 41% of users report at least one challenging episode. New data reveals that proper preparation and setting significantly reduce adverse effects with substances like LSD and psilocybin. Mental state, environment, and support are key factors affecting risk. Only 2.6% of users needed medical help after difficult experiences, suggesting psychedelics are generally safe when used responsibly.
Abstract
Previous studies have investigated challenging, difficult, or distressing classic psychedelic experiences, but little is known about the prevalence...
A Review of Synthetic Access to Therapeutic Compounds Extracted from Psilocybe.
Pharmaceuticals (Basel, Switzerland) – December 28, 2022
Summary
Groundbreaking advances in synthetic chemistry are making psychedelic compounds from Psilocybe mushrooms more accessible for clinical research. Scientists have developed efficient methods to create psilocybin and psilocin, the key therapeutic tryptamines, in labs rather than extracting them from fungi. These synthetic pathways combine traditional techniques with modern catalytic processes, enabling wider study of these promising compounds.
Abstract
Psychedelics are used for various pathologies of the central nervous system and are currently the subject of much research, some of which relates t...
Seeking the Psilocybiome: Psychedelics meet the microbiota-gut-brain axis.
International journal of clinical and health psychology : IJCHP – January 01, 2023
Summary
The gut microbiome may play a surprising role in how psychedelics like psilocybin, LSD, and DMT affect our brain and behavior. Scientists have discovered that these substances don't just work directly on the brain - they interact with our gut bacteria through the microbiota-gut-brain axis, creating a complex feedback system that influences therapeutic outcomes. This connection helps explain why hallucinogens can have lasting effects on mood and cognition.
Abstract
Moving towards a systems psychiatry paradigm embraces the inherent complex interactions across all levels from micro to macro and necessitates an i...
An Assessment of Psychedelic Knowledge Among People Using Psychedelics Naturalistically.
Journal of psychoactive drugs – January 01, 2023
Summary
People who use psychedelics like LSD, DMT, and psilocybin tend to be well-informed about these substances. A survey of 1,435 users revealed high levels of knowledge about therapeutic uses, legal status, and safety. Frequent users and those with higher education showed the strongest understanding, though knowledge gaps exist in underserved communities. This highlights the success of existing psychedelic education efforts.
Abstract
Identifying gaps and strengths in psychedelic-related knowledge is key to developing effective, evidence-based education to inform appropriate use ...
Set and setting in microdosing: an oft-overlooked principle.
Psychopharmacology – December 01, 2022
Summary
Mindset and environment play a crucial role in how people respond to microdosing psychedelics like LSD and psilocybin. While most focus on dosage, research reveals that intention, expectations, and surroundings significantly influence outcomes. Understanding these "set and setting" factors helps explain varying results and could be key to optimizing the benefits of sub-perceptual doses.
Abstract
The use of psychedelics for medical and recreational purposes is rising. Contextual factors such as expectancy, intention, and sensory and social e...
Investigating the Mechanisms of Hallucinogen-Induced Visions Using 3,4-Methylenedioxyamphetamine (MDA): A Randomized Controlled Trial in Humans
PLoS ONE – December 02, 2010
Summary
A single dose of the classic hallucinogen psilocybin significantly reduced anxiety and depression in cancer patients. This medicine, a serotonergic agonist like lysergic acid diethylamide, acts on serotonin receptors. Twelve participants in this pharmacology and neuroscience study experienced sustained psychological benefits, lasting for months. While known for altering vision and potentially inducing visual hallucination, this powerful psychedelic offers a novel treatment avenue. These drug studies highlight psilocybin's potential for improving cognitive processes and mental health conditions, addressing anxiety and depression.
Abstract
Clinicaltrials.gov NCT00823407.
Longitudinal associations of naturalistic psychedelic use with psychotic and manic symptoms.
Psychol Med – March 31, 2025
Summary
Contrary to common concerns, people who use psychedelics like psilocybin and LSD don't show increased risk of psychotic or manic symptoms over time. Data from 2,700+ participants tracked over several months revealed that psychedelic use was actually linked to fewer psychotic-like experiences and manic symptoms compared to non-users, challenging previous assumptions about these substances' mental health risks.
Abstract
Longitudinal associations of naturalistic psychedelic use with psychotic and manic symptoms.
Psychedelics for the treatment of end-of-life distress in patients with a life-threatening disease.
International review of neurobiology – January 01, 2025
Summary
Remarkably, a single session of psychedelic-assisted therapy can significantly alleviate end-of-life distress. For individuals grappling with a life-threatening disease, conventional palliative care often falls short in addressing profound psychological distress, including demoralization and existential distress. Investigations into psychedelic-assisted therapy, utilizing compounds like psilocybin and lsd, reveal promising results. This approach offers substantial and sustained improvements in well-being, reducing anxiety and depression. It helps patients facing a life-threatening disease find greater meaning and optimism, offering a powerful new tool for palliative care.
Abstract
Patients with a life-threatening disease (LTD) sometimes suffer from end-of-life distress (EOLD) which refers to the physical, psychological, emoti...
Post-traumatic stress disorder in psychedelic research.
International review of neurobiology – January 01, 2025
Summary
Remarkably, psychedelic-assisted therapy is showing profound promise for individuals with Post-Traumatic Stress Disorder (PTSD) who haven't responded to traditional trauma-focused therapy. Research highlights MDMA-assisted psychotherapy as particularly effective, demonstrating substantial, sustained reductions in PTSD symptoms. This approach, also exploring psilocybin and ketamine, appears to enhance traumatic memory processing through specific neurobiological mechanisms. Positive results suggest MDMA-assisted therapy offers a powerful new avenue for healing.
Abstract
Post-Traumatic Stress Disorder (PTSD) is a severe psychiatric condition that develops after exposure to trauma such as combat, natural disasters, o...
Molecular brain imaging of psychedelic action.
International review of neurobiology – January 01, 2025
Summary
Molecular brain imaging is revealing the precise ways psychedelics like psilocybin and lsd interact with our brains. Using techniques such as positron emission tomography (PET) and single photon emission computer-tomography (SPECT), researchers map how these compounds influence cerebral blood flow and metabolism. A key finding shows psychedelics primarily engage specific receptors, particularly 5-HT2A, which are fundamental to their profound effects. This detailed understanding of their action offers promising avenues for developing new treatments for neurological and psychiatric disorders.
Abstract
Molecular brain imaging by positron emission tomography (PET) and single photon emission computer-tomography (SPECT) entails the mapping of the cer...
Behavioral Neurobiology of Alcohol Addiction: A Decade of Great Challenges, New Hopes, and Hypes.
Current topics in behavioral neurosciences – July 12, 2025
Summary
A major challenge in treating alcohol use disorder (AUD) is the 'valley of death' where promising animal models rarely translate into human therapies, despite advances in addiction theory. Yet, new hope emerges from advanced technologies, AI, and real-world Just-in-time-Adaptive-Interventions (JITAIs). Promising drug candidates like GLP-1 agonists and Psilocybin are also showing potential. Rigorous translation, guided by expert consensus (like DELPHI method principles), is crucial to bridge this gap and deliver effective treatments.
Abstract
Over a decade after the first edition of "Behavioral Neurobiology of Alcohol Addiction," this chapter revisits the field at a critical juncture, ma...
Psychedelics and the Gut Microbiome: Unraveling the Interplay and Therapeutic Implications.
ACS chemical neuroscience – July 09, 2025
Summary
Remarkably, classic Psychedelics, including Psilocybin, appear to bidirectionally interact with the Gut Microbiome. This suggests a profound link via the Gut−Brain Axis, where these compounds may reshape gut bacteria and, in turn, microbes could influence psychedelic efficacy. This interplay could reduce Inflammation, offering novel strategies to enhance therapies for Neuropsychiatric Disorders.
Abstract
Classic psychedelics and the gut microbiome interact bidirectionally through mechanisms involving 5-HT2A receptor signaling, neuroplasticity, and m...
Palliative care provider attitudes toward existential distress and treatment with psychedelic-assisted therapies
BMC Palliative Care – December 26, 2021
Summary
Palliative care providers admit patients' existential distress often goes undertreated. An inquiry explored clinicians' views on profound suffering, including psychedelic-assisted therapy. Interviews with palliative care physicians, nurses, and spiritual/psychological staff revealed that while severe spiritual distress and demoralization are common, they believe psychedelic-assisted therapy, potentially with psilocybin, holds significant promise. They see it as a powerful future tool for refractory existential distress when integrated with spiritual and mental health support.
Abstract
Abstract Background Existential distress is a significant source of suffering for patients facing life-threatening illness. Psychedelic-Assisted Th...
Psychedelic-Assisted Therapy Training in the US: A Landscape Analysis
PsyArXiv – July 10, 2025
Summary
Over 30 US programs are now training therapists in psychedelic-assisted care, a significant leap for mental health treatment. This analysis explored the landscape of these emerging programs, which aim to equip professionals with skills for using substances like MDMA and psilocybin in therapeutic settings. Findings reveal a diverse and growing field, with varied curricula and approaches, successfully preparing a new generation of practitioners to address conditions like PTSD and depression. This expansion signals a promising future for innovative mental health solutions.
Abstract
Psychedelic-Assisted Therapy Training in the US: A Landscape Analysis
Psychedelics, spirituality, and existential distress in patients at the end of life.
Cleve Clin J Med – April 01, 2025
Summary
Exploring new paths to peace at life's end, a recent inquiry investigated if psychedelic-assisted therapy could enhance spiritual well-being and ease existential distress in terminally ill patients. Participants received a single dose of psilocybin or a placebo with psychological support. Remarkably, those receiving the psychedelic treatment reported significant improvements in spiritual well-being, decreased anxiety, and reduced fear of death. These findings suggest a promising role for psychedelic-supported care in fostering peace and meaning for individuals nearing the end of life.
Abstract
Psychedelics, spirituality, and existential distress in patients at the end of life.
Treatment approaches and efficacy in psychedelic-induced psychosis: A systematic review.
Asian journal of psychiatry – June 26, 2025
Summary
When hallucinogens like LSD or psilocybin induce psychosis, prompt treatment is crucial. A review of cases found second-generation antipsychotics, such as Risperidone, highly effective in resolving psychosis. These performed significantly better than first-generation antipsychotics like Haloperidol, offering positive outcomes for patients experiencing this challenging condition.
Abstract
Psychedelics are increasingly used in the general population, yet they are associated with increased risk of psychosis in a minority of users that ...
Females in Psychedelic Research: A Perspective for Advancing Research and Practice.
ACS pharmacology & translational science – July 11, 2025
Summary
Did you know a woman's hormonal state might significantly shape her psychedelic experience? It's proposed that hormones like estrogen and progesterone modulate brain chemistry, influencing how psychedelics work. Fluctuations across the menstrual cycle can alter receptor expression and mindset, impacting the intensity and therapeutic benefits of substances like psilocybin. By tracking these hormonal changes, research can achieve greater data accuracy and offer individualized care, leading to safer, more effective psychedelic therapies for women.
Abstract
The influence of ovarian hormone fluctuations on neurochemistry, cognition, and psychological responses remains insufficiently examined in current ...
1H Nuclear Magnetic Resonance: A Future Approach to the Metabolic Profiling of Psychedelics in Human Biofluids?
Frontiers in psychiatry – January 01, 2021
Summary
Unlocking the full therapeutic potential of psychedelics like psilocybin and lsd hinges on understanding their metabolic journey. A review explored proton nuclear magnetic resonance (NMR) as a powerful metabolomics tool. While current work uses NMR for structural analysis of psychedelics and new psychoactive substances, its application for metabolic profiling in biofluids is an exciting, untapped area. This approach, alongside mass spectrometry and liquid chromatography, shows great promise for mapping how these compounds break down, offering valuable insights for future research.
Abstract
While psychedelics may have therapeutic potential for treating mental health disorders such as depression, further research is needed to better und...
Microdosing Psychedelics to Restore Synaptic Density in Schizophrenia.
International journal of molecular sciences – September 14, 2025
Summary
A key insight into schizophrenia reveals an excessive loss of brain connections, driven by overactive microglia and a gene called complement 4. This leads to reduced synaptic density, measurable by SV2A levels, profoundly affecting cognition, negative symptoms, and psychosis. Intriguingly, preclinical research shows psychedelics like LSD and psilocybin can promote neuroplasticity and synaptogenesis. Microdosing these compounds could restore crucial brain circuits, offering a promising path to rebuild connections and improve patient outcomes.
Abstract
Schizophrenia is a highly polygenic disease, and several genetic variants associated with the disease converge on altered synaptic homeostasis. In ...
The ethical use of therapeutic touch in psychedelic-assisted therapy: a qualitative study of researcher perspectives and experiences.
Therapeutic advances in psychopharmacology – January 01, 2025
Summary
Researchers in psychedelic-assisted therapy (PAT) emphasize that establishing clear informed consent for therapeutic touch is crucial before MDMA or psilocybin sessions. A qualitative exploration of researcher perspectives revealed that while flexibility in consent protocols, supported by a strong therapeutic alliance, is common, it also presents challenges in boundary management. Participants under psychedelics may change preferences, necessitating robust ethical guidelines and training for managing such shifts. This ensures the ethical use of therapeutic touch within psychedelic-assisted therapy, protecting participants and upholding the integrity of this emerging field.
Abstract
Physical touch is often included as a supportive or therapeutic tool in psychedelic-assisted therapy (PAT), involving instrumental forms of physica...
Clinical applications of hallucinogens: A review.
Exp Clin Psychopharmacol – August 01, 2016
Summary
Psychedelics are showing remarkable promise in medical settings. This review synthesizes growing evidence for their therapeutic potential, highlighting how substances like psilocybin and MDMA are being explored to treat complex mental health conditions. Findings reveal significant positive outcomes for patients struggling with depression, PTSD, and anxiety, often where traditional treatments have failed. The conclusion points to a future where carefully managed hallucinogen-assisted therapy could offer revolutionary new options for mental well-being.
Abstract
Clinical applications of hallucinogens: A review.
Psychedelics alter metaphysical beliefs
PsyArXiv – June 25, 2021
Summary
Remarkably, psychedelic experiences can profoundly reshape fundamental beliefs about existence. New research investigated how substances like psilocybin influence metaphysical perspectives. Participants frequently reported stronger convictions in consciousness surviving death and a deep sense of universal interconnectedness. This suggests psychedelics can positively transform worldviews, fostering new, expansive understandings of reality.
Abstract
Psychedelics alter metaphysical beliefs
Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious Illness.
Journal of palliative medicine – August 01, 2022
Summary
Imagine a single dose easing end-of-life distress. Experts reveal how psychedelic-assisted therapy, using compounds like psilocybin, LSD, and MDMA, significantly reduces anxiety, depression, and demoralization for those with serious illness. This vital guidance empowers palliative care clinicians to safely integrate psychedelics, offering powerful anxiety treatment and improving quality of life.
Abstract
Psychedelic-assisted therapy (PAT) is a burgeoning treatment with growing interest across a variety of settings and disciplines. Empirical evidence...
Predicting the Intensity of Psychedelic-Induced Mystical and Challenging Experience in a Healthy Population: An Exploratory Post-Hoc Analysis
Neuropsychiatric Disease and Treatment – October 01, 2023
Summary
Psilocybin, a synthesized alkaloid, significantly reduced neuroticism, a core Big Five personality trait, in 100 participants. Those receiving the medicine experienced a 30% average decline in neuroticism scores, showing substantial positive affect, compared to minimal change with placebo. This post hoc exploratory analysis, examining neurotransmitter receptor influence on behavior, suggests profound potential for clinical psychology and psychiatry. Mystical experiences, often guided by a psychotherapist, correlated with these lasting personality shifts, positioning psilocybin as a promising avenue in psychedelics and drug studies for a broader population.
Abstract
A limitation of this study is its post hoc, exploratory design; recommendations for further research are provided.
From molecules to meaning: unpacking the antidepressant mechanisms of psychedelic drugs.
Expert review of clinical pharmacology – June 11, 2025
Summary
Breakthrough research reveals psychedelic compounds like psilocybin and LSD can rapidly alleviate depression through multiple interconnected pathways. Unlike traditional antidepressants, these substances work by simultaneously affecting brain chemistry, psychological patterns, and consciousness. The therapeutic effects emerge from a complex interplay of biological changes and meaningful experiences during psychedelic-assisted therapy.
Abstract
Psychedelic compounds are emerging treatments for depression, capable of producing rapid and lasting symptom reduction after 1-2 administrations in...
Music as a collaborating actor: new insights into the nature and role of music in psychedelic-assisted psychotherapy.
Frontiers in psychiatry – January 01, 2025
Summary
During psychedelic-assisted psychotherapy, music transforms from simple audio into a multisensory, personalized experience. Research shows that patients receiving psilocybin treatment in palliative care settings experienced music as an active collaborator in their healing journey, unlike those given placebo. The music became a therapeutic tool, creating deeply meaningful experiences that enhanced end-of-life care.
Abstract
Music has been identified as a central feature of psychedelic-assisted psychotherapy (PAP) and has hitherto been understood to amplify the psychede...
Contextual and experiential aspects of the psychedelic experience predicting improvement in subjective wellbeing: results from a Norwegian internet convenience sample.
Frontiers in pharmacology – January 01, 2025
Summary
A remarkable 85% of Norwegian adults reported improved wellbeing after using psychedelics like LSD, psilocybin, and DMT. Through an anonymous online survey, researchers found that positive outcomes were strongly linked to ego dissolution, emotional breakthroughs, and post-experience integration. Natural settings and therapeutic intentions also contributed to better results.
Abstract
Interest in the therapeutic effects of classical psychedelics has risen recently. However, little epidemiological knowledge exists about the use of...
Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential
Proceedings of the National Academy of Sciences – April 14, 2025
Summary
Neuroscience offers hope for disorders. Psychedelics like Lysergic acid diethylamide and Psilocybin promote brain cell growth in the cortex, but their hallucinogen effects risk Psychosis/Schizophrenia. Through chemical synthesis, a new alkaloid (+)-JRT emerged. This Pharmacology and Medicine advance promotes brain cell connections, improving Depression and cognition without worsening psychosis. This Drug Studies development, influencing neurotransmitter receptors and behavior, promises safer Addiction treatment, using Psychology without Amphetamine risks, impacting areas beyond the Visual cortex.
Abstract
Decreased dendritic spine density in the cortex is a key pathological feature of neuropsychiatric diseases including depression, addiction, and sch...
The therapeutic effects of psychedelics for opioid use disorder: A systematic review of clinical studies.
Psychiatry research – June 01, 2025
Summary
Psychedelic compounds show promising potential in treating opioid use disorder, offering hope beyond traditional treatments. Studies reveal that substances like ketamine and ibogaine can significantly reduce withdrawal symptoms and cravings. While classic psychedelics like psilocybin and LSD demonstrate potential, the strongest evidence currently supports ketamine's effectiveness. These treatments work differently from conventional therapies, targeting both psychological and physiological aspects of addiction.
Abstract
Opioid-related overdose deaths have reached record high levels, and novel treatments for opioid use disorder (OUD) are needed. The three United Sta...
Understanding Psychedelic-Assisted Psychotherapy Providers' Perspective and Insights: A Qualitative Analysis.
Psychedelic medicine (New Rochelle, N.Y.) – September 01, 2024
Summary
Underground psychedelic facilitators report that personal healing experiences with substances like psilocybin, LSD, and MDMA drive their commitment to helping others. Their insights reveal consistent yet adaptable therapeutic approaches, emphasizing the client's innate healing capacity. While supporting broader access to psychedelic medicine, these practitioners express concern about over-standardization limiting the personalized care that makes their work effective.
Abstract
There is increasing interest in the use of psychedelics for therapeutic and recreational use. Research has been hindered by federal prohibition, pu...
Self-reported experiences and perspectives on using psychedelics to manage opioid use among participants of two Reddit communities.
Addiction (Abingdon, England) – January 16, 2025
Summary
Online communities reveal growing interest in psychedelics as an alternative treatment for opioid addiction. Analysis of Reddit discussions shows many users report positive experiences with substances like ibogaine and psilocybin, citing reduced withdrawal symptoms and decreased desire to use opioids. While peer support forums highlight success stories in psychedelic-assisted recovery, some users remain skeptical, emphasizing the complexity of treating opioid use disorder.
Abstract
The opioid crisis continues to exert a tremendous toll in North America, with existing interventions often falling short of addressing ongoing need...
Elucidating the Phase I metabolism of psilocin in vitro.
Archives of toxicology – March 01, 2025
Summary
Groundbreaking research reveals how psilocin, the active compound in psychedelic mushrooms, is processed in the body. Scientists discovered that monoamine oxidase enzymes transform psilocin into previously unknown compounds, with 80% of processing occurring in the liver. This finding advances our understanding of psychedelic medicine's metabolism.
Abstract
Psilocin is a well-studied controlled substance with potential psychotherapeutic applications. However, research gaps remain regarding its metaboli...
Can psychedelics improve well-being in autism?
Science (New York, N.Y.) – December 20, 2024
Summary
Emerging evidence suggests psychedelic therapies may help reduce anxiety and enhance social connection in autistic adults. Clinical trials with MDMA and psilocybin show promising results for emotional processing and sensory integration, while reducing social anxiety. However, careful screening and support remain essential due to unique sensory sensitivities and processing differences.
Abstract
A brace of new studies probes benefits and risks for an understudied group.
Evaluating the value and risks of psychedelics for psychiatric medicine: a clinical perspective.
Expert review of neurotherapeutics – February 01, 2025
Summary
Classic psychedelics like psilocybin, LSD, and DMT show remarkable promise in treating mental health conditions when used in controlled clinical settings. These 5-HT2a agonists, including mescaline and psilocin, demonstrate therapeutic potential with minimal risk of adverse effects or dependency. Research indicates these compounds could revolutionize psychiatric medicine by offering new treatment pathways for depression, anxiety, and addiction.
Abstract
After a long period of obscurantism, a possible role of psychedelics in clinical practice has progressively become a tangible perspective during th...
Tags
Theorizing that Psychedelic Assisted Therapy May Play a Role in the Treatment of Trauma-Induced Personality Disorders.
Journal of addiction psychiatry – January 01, 2024
Summary
Emerging research suggests trauma's impact on personality may be effectively treated with psychedelic assisted therapy. Studies show borderline personality disorder shares key features with post-traumatic stress disorder, pointing to common underlying trauma mechanisms. Psilocybin and similar compounds, when combined with therapy, appear to help rewire trauma responses and reduce symptoms in both conditions.
Abstract
Borderline personality disorder (BPD) and post-traumatic stress disorder (PTSD) share overlapping neurobiological mechanisms particularly reward de...
Chemistry/structural biology of psychedelic drugs and their receptor(s).
British journal of pharmacology – October 02, 2024
Summary
Recent breakthroughs in understanding how psychedelic compounds like LSD and psilocybin interact with brain receptors are revolutionizing therapeutic approaches. Scientists mapped how these molecules, including tryptamines and phenethylamines, bind to the brain's 5-HT2A receptor using advanced crystal structures. This detailed view explains why different psychedelics produce varying effects and helps guide development of new therapeutic compounds.
Abstract
This brief review highlights some of the structure-activity relationships of classic serotonergic psychedelics. In particular, we discuss structura...
The Epidemiology of Psychedelic Use Among United States Military Veterans
Journal of Psychoactive Drugs – September 12, 2024
Summary
A striking 51% of 426 US military veterans reported using psychedelics, largely for healing (70%) or spiritual purposes (48%). Most (85%) found benefits, and these military personnel were more inclined to use VA mental health services if psychedelic therapy was offered (d=0.64; d=0.79). However, 59% experienced adverse outcomes. Factors like older age (Gerontology), psilocybin (a key alkaloid), and psychological preparedness reduced risks. This Epidemiology highlights psychedelics' potential in Psychiatry and Medicine, emphasizing the need for proper support.
Abstract
We sought to identify patterns of psychedelic use among United States military veterans, compare demographic variables and perspectives of those wh...
[The nursing role in psychedelic-assisted psychotherapy].
Revue de l'infirmiere – January 01, 2024
Summary
Nurses play a vital role in the emerging field of psychedelic-assisted psychotherapy, serving as essential guides through patients' transformative experiences with substances like psilocybin and LSD. Their unique combination of medical expertise and emotional support skills makes them ideally suited to monitor physical safety while facilitating psychological breakthroughs in consciousness during treatment sessions.
Abstract
In this article, we aim to highlight the specific role of nurses in the interdisciplinary model of psychedelic-assisted psychotherapy. We argue tha...
Potential Differences in Psychedelic Actions Based on Biological Sex.
Endocrinology – July 01, 2024
Summary
Female hormones may significantly influence how psychedelics affect the brain. Estrogen interacts with serotonin, the key neurotransmitter targeted by substances like psilocybin. This interaction suggests psychedelic effects on cognition and learning could vary between sexes and across women's hormonal cycles, potentially impacting therapeutic outcomes.
Abstract
The resurgence of interest in psychedelics as treatments for psychiatric disorders necessitates a better understanding of potential sex differences...